These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7059416)

  • 41. Binding and antimineralocorticoid activities of spirolactones in toad bladder.
    Rossier BC; Claire M; Rafestin-Oblin ME; Geering K; Gäggeler HP; Corvol P
    Am J Physiol; 1983 Jan; 244(1):C24-31. PubMed ID: 6217754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 43. Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
    Hoffbrand BI; Edmonds CJ; Smith T
    Br Med J; 1976 Mar; 1(6011):682-4. PubMed ID: 766908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.
    Bamberg K; William-Olsson L; Johansson U; Jansson-Löfmark R; Hartleib-Geschwindner J
    J Renin Angiotensin Aldosterone Syst; 2019; 20(1):1470320319827449. PubMed ID: 30813831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
    Whitworth JA; Kelly JJ
    J Endocrinol Invest; 1995; 18(7):586-91. PubMed ID: 9221279
    [No Abstract]   [Full Text] [Related]  

  • 46. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spironolactone in thiazide-induced hypokalaemia: variable response between patients.
    Ramsay LE; Hettiarachchi J
    Br J Clin Pharmacol; 1981 Feb; 11(2):153-8. PubMed ID: 7213519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimineralocorticoids.
    Agarwal MK; Lazar G
    Ren Physiol Biochem; 1991; 14(6):217-23. PubMed ID: 1720252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
    Nariai T; Fujita K; Kawane K; Mori M; Nakayama R; Matsuda K; Katayama S; Fukuda N; Hori S; Iwata M; Hasegawa F; Suzuki K; Kato H
    J Pharmacol Exp Ther; 2015 Jul; 354(1):2-9. PubMed ID: 25922341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of food intake on antihypertensive drugs: spironolactone.
    Thulin T; Wåhlin-Boll E; Liedholm H; Lindholm L; Melander A
    Drug Nutr Interact; 1983; 2(3):169-73. PubMed ID: 6678756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aldosterone is a physiologically significant kaliuretic hormone.
    Adam WR; Ellis AG; Adams BA
    Am J Physiol; 1987 Jun; 252(6 Pt 2):F1048-54. PubMed ID: 3296784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
    Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
    Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of endogenous mineralocorticoids on the composition of fetal urine.
    Kairaitis K; Lumbers ER
    J Dev Physiol; 1990 Jun; 13(6):347-51. PubMed ID: 2084194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients.
    Vlassopoulos D; Sonikian M; Dardioti V; Pani I; Hadjilouka-Mantaka A; Hadjiconstantinou V
    Ren Fail; 2001 Nov; 23(6):833-42. PubMed ID: 11777323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.
    Quinkler M; Meyer B; Oelkers W; Diederich S
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3767-72. PubMed ID: 12915667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human assay of electrolyte-active steroids and their antagonists.
    ROSS EJ
    Clin Sci; 1962 Oct; 23():197-202. PubMed ID: 13975085
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparative dose-effect studies with four C-17-spirosteroidal mineralocorticoid synthesis inhibitors.
    Weindel K; Lewicka S; Vecsei P
    J Steroid Biochem; 1989; 34(1-6):455-9. PubMed ID: 2626039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.
    Brandish PE; Chen H; Szczerba P; Hershey JC
    J Pharmacol Toxicol Methods; 2008; 57(2):155-60. PubMed ID: 18304838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.